Blogs about: Thalomid
Featured Blog
JP Morgan Update:Can Celgene become a "Niche Buster" Factory?
Sol Barer, PhD, CEO of Celgene (NASDAQ:CELG) announced at the JP Morgan Conference in San Francisco, exciting developments in in label expanding clinical trials for Revlimid including in the treatm… more »
BioBusinessBlog
Multiple Myeloma First-Line Treatment Study at CORT
bmirtsching wrote 1 month ago: Treatment options for multiple myeloma have significantly expanded over the past decade with the dev … more »
JP Morgan Update:Can Celgene become a "Niche Buster" Factory?
stephanedenepoux wrote 4 months ago: Sol Barer, PhD, CEO of Celgene (NASDAQ:CELG) announced at the JP Morgan Conference in San Francisco … more »
Have your say. Start a blog.
See our free features »
Copyright 2008 Automattic, Inc.
An 
Production
